Intra-Cellular Therapies, Inc. (ITCI)
USD 131.87
(0.0%)
USD 131.87
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 590 Million USD | 19.4% |
| 2022 | 492.31 Million USD | 37.0% |
| 2021 | 359.36 Million USD | 42.68% |
| 2020 | 251.86 Million USD | 63.47% |
| 2019 | 154.07 Million USD | -5.05% |
| 2018 | 162.26 Million USD | 57.41% |
| 2017 | 103.08 Million USD | -13.07% |
| 2016 | 118.58 Million USD | 11.98% |
| 2015 | 105.9 Million USD | 235.53% |
| 2014 | 31.56 Million USD | 8.83% |
| 2013 | 29 Million USD | 48.57% |
| 2012 | 19.52 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 155.91 Million USD | 0.66% |
| 2024 Q3 | 198.7 Million USD | 11.78% |
| 2024 Q2 | 177.75 Million USD | 14.01% |
| 2023 Q4 | 154.9 Million USD | 5.81% |
| 2023 FY | 587.81 Million USD | 19.4% |
| 2023 Q1 | 136.37 Million USD | 6.49% |
| 2023 Q2 | 150.14 Million USD | 10.1% |
| 2023 Q3 | 146.39 Million USD | -2.5% |
| 2022 FY | 492.31 Million USD | 37.0% |
| 2022 Q4 | 128.05 Million USD | 5.27% |
| 2022 Q3 | 121.64 Million USD | -12.07% |
| 2022 Q2 | 138.34 Million USD | 32.69% |
| 2022 Q1 | 104.26 Million USD | -4.33% |
| 2021 Q4 | 108.98 Million USD | 12.44% |
| 2021 Q3 | 96.92 Million USD | 12.57% |
| 2021 FY | 359.36 Million USD | 42.68% |
| 2021 Q1 | 67.34 Million USD | -7.24% |
| 2021 Q2 | 86.1 Million USD | 27.87% |
| 2020 Q1 | 49.89 Million USD | 19.29% |
| 2020 FY | 251.86 Million USD | 63.47% |
| 2020 Q2 | 66.61 Million USD | 33.51% |
| 2020 Q3 | 62.74 Million USD | -5.81% |
| 2020 Q4 | 72.59 Million USD | 15.69% |
| 2019 Q1 | 36.69 Million USD | -13.91% |
| 2019 Q4 | 41.82 Million USD | 14.99% |
| 2019 Q2 | 39.17 Million USD | 6.75% |
| 2019 Q3 | 36.37 Million USD | -7.14% |
| 2019 FY | 154.07 Million USD | -5.05% |
| 2018 Q4 | 42.62 Million USD | -1.77% |
| 2018 FY | 162.26 Million USD | 57.41% |
| 2018 Q3 | 43.39 Million USD | 10.78% |
| 2018 Q2 | 39.16 Million USD | 5.62% |
| 2018 Q1 | 37.08 Million USD | 13.36% |
| 2017 Q3 | 23.78 Million USD | 26.99% |
| 2017 Q2 | 18.73 Million USD | -32.73% |
| 2017 Q1 | 27.84 Million USD | -1.0% |
| 2017 FY | 103.08 Million USD | -13.07% |
| 2017 Q4 | 32.71 Million USD | 37.51% |
| 2016 Q4 | 28.13 Million USD | -6.82% |
| 2016 Q3 | 30.18 Million USD | -4.98% |
| 2016 FY | 118.58 Million USD | 11.98% |
| 2016 Q1 | 28.49 Million USD | -3.08% |
| 2016 Q2 | 31.77 Million USD | 11.49% |
| 2015 Q2 | 21.74 Million USD | -2.93% |
| 2015 FY | 105.9 Million USD | 235.53% |
| 2015 Q4 | 29.4 Million USD | -9.11% |
| 2015 Q3 | 32.34 Million USD | 48.74% |
| 2015 Q1 | 22.4 Million USD | 45.83% |
| 2014 Q4 | 15.36 Million USD | 131.79% |
| 2014 Q2 | 4.83 Million USD | 1.87% |
| 2014 Q3 | 6.62 Million USD | 37.2% |
| 2014 FY | 31.56 Million USD | 8.83% |
| 2014 Q1 | 4.74 Million USD | -46.48% |
| 2013 Q2 | 10.81 Thousand USD | -98.97% |
| 2013 Q3 | 5.45 Million USD | 50309.62% |
| 2013 Q1 | 1.04 Million USD | -6.45% |
| 2013 FY | 29 Million USD | 48.57% |
| 2013 Q4 | 8.86 Million USD | 62.48% |
| 2012 Q4 | 1.11 Million USD | 0.0% |
| 2012 FY | 19.52 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -7049.099% |
| Alpha Teknova, Inc. | 45.85 Million USD | -1186.565% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | -201.05% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -1215.392% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -270.588% |
| Cosmos Health Inc. | 26.18 Million USD | -2153.584% |
| Journey Medical Corporation | 54.59 Million USD | -980.716% |
| Embecta Corp. | 528.4 Million USD | -11.659% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -116.996% |
| Dynavax Technologies Corporation | 219.14 Million USD | -169.231% |
| Pacira BioSciences, Inc. | 326.37 Million USD | -80.774% |
| PainReform Ltd. | 9.58 Million USD | -6056.156% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -4395.465% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -4395.465% |
| SCYNEXIS, Inc. | 51.84 Million USD | -1037.953% |
| Safety Shot Inc | 12.1 Million USD | -4772.179% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -19123.521% |
| Procaps Group, S.A. | 199.47 Million USD | -195.776% |
| Theratechnologies Inc. | 72.75 Million USD | -710.938% |
| Harrow Health, Inc. | 89.97 Million USD | -555.759% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -6146.094% |
| Biofrontera Inc. | 39.95 Million USD | -1376.528% |
| DURECT Corporation | 43.71 Million USD | -1249.665% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -11.53% |
| Cronos Group Inc. | 96.7 Million USD | -510.084% |
| OptiNose, Inc. | 85.1 Million USD | -593.293% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | -154.177% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -1406.924% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 6270.965% |
| Organogenesis Holdings Inc. | 314.13 Million USD | -87.82% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -5963.262% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -1270.814% |
| Radius Health, Inc. | 265.92 Million USD | -121.866% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -4162.462% |
| ProPhase Labs, Inc. | 37.85 Million USD | -1458.718% |
| Phibro Animal Health Corporation | 260.29 Million USD | -126.666% |
| Procaps Group S.A. | 187.24 Million USD | -215.098% |
| Alvotech | 285.43 Million USD | -106.702% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -5905.15% |
| Viatris Inc. | 5.96 Billion USD | 90.111% |
| Rockwell Medical, Inc. | 15.37 Million USD | -3737.687% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -885.973% |
| SIGA Technologies, Inc. | 22.04 Million USD | -2576.611% |
| Tilray Brands, Inc. | 251.35 Million USD | -134.728% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -1103.161% |
| Shineco, Inc. | 17.94 Million USD | -3187.301% |
| PetIQ, Inc. | 192.72 Million USD | -206.139% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -14682.902% |
| Incannex Healthcare Limited | 30.05 Million USD | -1863.218% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 63.044% |
| Alimera Sciences, Inc. | 62.64 Million USD | -841.885% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -77278.648% |
| Assertio Holdings, Inc. | 368.58 Million USD | -60.073% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -9924.618% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -3213.052% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -2687.123% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -2703.932% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -257.653% |
| Hempacco Co., Inc. | 7.59 Million USD | -7666.866% |
| Talphera, Inc. | 11.99 Million USD | -4819.176% |
| Alvotech | 285.43 Million USD | -106.702% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -319.294% |
| Lantheus Holdings, Inc. | 344.9 Million USD | -71.065% |
| Currenc Group, Inc. | 24 Million USD | -2358.144% |
| Kamada Ltd. | 45.42 Million USD | -1198.829% |
| Indivior PLC | 911 Million USD | 35.235% |
| Evoke Pharma, Inc. | 12.4 Million USD | -4654.416% |
| Flora Growth Corp. | 10.57 Million USD | -5477.143% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -2703.932% |
| Evolus, Inc. | 189.75 Million USD | -210.924% |
| HUTCHMED (China) Limited | 436.23 Million USD | -35.251% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -282.788% |
| Akanda Corp. | 3.48 Million USD | -16837.122% |